Steve Rusckowski

Quest processes over 200 million patient samples annually through a network of more than 2,250 patient service centers and a fleet of reference laboratories, offering approximately 3,000 different diagnostic tests ranging from routine blood work to advanced genetic and molecular testing. Quest has been investing in consumer-initiated testing — allowing individuals to order certain lab tests directly through the Quest app or website without a physician's order. This direct-to-consumer approach taps into growing consumer interest in proactive health monitoring and represents a potential expansion of the addressable market beyond physician-ordered testing. The company also provides employer wellness testing, drug testing, and health risk assessments. The clinical laboratory industry benefits from several structural tailwinds: aging population (older patients require more frequent testing), precision medicine (genomic and molecular tests are becoming standard of care), and the growing role of diagnostics in healthcare value-based care models. Key stock drivers include base business testing volumes, advanced diagnostics test mix improvement, consumer-initiated testing growth, reimbursement rates from insurance payers, competition with Labcorp and hospital-based laboratories, the pace of test innovation (particularly in oncology and genomics), and overall U.S. healthcare utilization trends.